Literature DB >> 23959652

Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation.

Neil Mehta1, Francis Y Yao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23959652     DOI： 10.1002/lt.23730

Source DB:  PubMed          Journal:  Liver Transpl        ISSN： 1527-6465            Impact factor:   5.799


× No keyword cloud information.
  19 in total

Review 1.  When to consider liver transplantation in hepatocellular carcinoma patients?

Authors:  Ka Wing Ma; Tan To Cheung
Journal:  Hepat Oncol       Date:  2017-07-06

2.  Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study.

Authors:  Neil Mehta; Jennifer Guy; Catherine T Frenette; Jennifer L Dodge; Robert W Osorio; William B Minteer; John P Roberts; Francis Y Yao
Journal:  Clin Gastroenterol Hepatol       Date:  2017-11-23       Impact factor: 11.382

3.  Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.

Authors:  Quirino Lai; Milton Inostroza; Juan M Rico Juri; Pierre Goffette; Jan Lerut
Journal:  HPB (Oxford)       Date:  2015-09-16       Impact factor: 3.647

4.  Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Francis Y Yao; John Paul Roberts
Journal:  Liver Transpl       Date:  2014-07-03       Impact factor: 5.799

5.  Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.

Authors:  Bilal Hameed; Neil Mehta; Gonzalo Sapisochin; John P Roberts; Francis Y Yao
Journal:  Liver Transpl       Date:  2014-07-12       Impact factor: 5.799

6.  Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.

Authors:  Neil Mehta; Jennifer L Dodge; John P Roberts; Francis Y Yao
Journal:  Am J Transplant       Date:  2017-12-02       Impact factor: 8.086

7.  Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.

Authors:  Neil Mehta; Jennifer L Dodge; John P Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Hepatology       Date:  2019-02-10       Impact factor: 17.425

8.  Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".

Authors:  Neil Mehta; Julie Heimbach; David Lee; Jennifer L Dodge; Denise Harnois; Justin Burns; William Sanchez; John P Roberts; Francis Y Yao
Journal:  Transplantation       Date:  2017-09       Impact factor: 4.939

9.  Impact of pathological features of primary hepatocellular carcinoma on the outcomes of intrahepatic recurrence management: single center experience from Southern Taiwan.

Authors:  Mahmoud Abdelwahab Ali; Wei-Feng Li; Jing-Houng Wang; Chih-Che Lin; Ying-Ju Chen; Ting-Lung Lin; Tsan-Shiun Lin; Sheng-Nan Lu; Chih-Chi Wang; Chao-Long Chen
Journal:  HPB (Oxford)       Date:  2016-08-25       Impact factor: 3.647

Review 10.  Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.

Authors:  Taizo Hibi; Osamu Itano; Masahiro Shinoda; Yuko Kitagawa
Journal:  Surg Today       Date:  2016-04-29       Impact factor: 2.549
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.